Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: A 3.5-year study

Journal of Acquired Immune Deficiency Syndromes

Volumn 28, Issue 4, 2001, Pages 332-335

  Mahajan, Anish P ^a   Tashima, Karen T ^a   Bausserman, Linda L ^a   Flynn, Mary M ^a   Carpenter, Charles C J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

Antiretroviral therapy; Fat redistribution; HIV in women; Hyperlipidemia; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LIPID; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0035576290     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200112010-00004     Document Type: Article

References (12)

1. Diagnosis, prediction, and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus
2. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
3. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
4. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
5. Fasting hyperinsulinemia and changes in regional body composition in human-immunodeficiency virus-infected women
6. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
7. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
8. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS)
9. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance
10. Visceral abdominal fat accumulation associated with use of indinavir
11. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: A prospective cohort study
12. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection